ROCKVILLE, Md., May 22, 2015 /PRNewswire/ -- RegeneRx
Biopharmaceuticals, Inc. (OTCQB: RGRX), a clinical-stage drug
development company focused on tissue protection, repair and
regeneration, today announced that J.J.
Finkelstein, chief executive officer of RegeneRx, is
scheduled to present a corporate overview at two upcoming investor
conferences.
Mr. Finkelstein will present at the SeeThruEquity 4th
Annual Microcap Conference on Thursday May
28, 2015 in New York City
at 11:00 am EDT. A webcast will
be available at the time of the presentation and for 90 days at
http://wsw.com/webcast/seethru11/rgrx. The investor
presentation will also be posted on RegeneRx's web site at
http://regenerx.investorroom.com/presentations.
On Tuesday June 2, 2015, Mr.
Finkelstein will present at the 5th Annual LD Micro
Invitational Conference in Los Angeles,
CA at 11:30am PT.
About RegeneRx Biopharmaceuticals, Inc.
(www.regenerx.com)
RegeneRx is focused on the development of a novel therapeutic
peptide, Thymosin beta 4, for tissue and organ protection, repair
and regeneration. RegeneRx currently has three drug candidates in
clinical development for ophthalmic, cardiac and dermal
indications, three active strategic licensing agreements in
China, Pan Asia (Korea,
Japan, and Australia, among others) and in the U.S.
RGN-259, the Company's TB-based ophthalmic drug candidate is being
developed for dry eye syndrome and for the treatment of
neurotrophic keratopathy (NK), both of which are being developed in
the U.S through its joint venture, ReGenTree. RGN-259 has
been granted orphan status by the U.S. FDA and was recently allowed
by the FDA to move into phase 3 clinical trials for the treatment
of patients with NK. RGN-352, the Company's TB-based
injectable drug candidate, is a phase 2-ready drug candidate
designed to be administered systemically to prevent and restore
tissue damage associated with acute events such as heart attacks,
strokes, and other similar injuries. RGN-137, the Company's
TB-based dermal gel, is in phase 2 clinical development. For
additional information about RegeneRx please visit
www.regenerx.com.
Forward-Looking Statements
Any statements in this press release that are not historical
facts are forward-looking statements made under the provisions of
the Private Securities Litigation Reform Act of 1995. Any
forward-looking statements and information presented by the company
at investor conferences or via webcasts involve risks and
uncertainties that could affect any future outcomes expressed or
implied by such forward-looking statements. There can be no
assurance that any clinical trial, sponsored by the Company or any
third party, will be able to be performed on time and establish
safety and efficacy necessary for regulatory approval, or that any
drug candidate that is the subject of such trial will prove to be
commercially valuable. There can be no assurance that any of
the Company's drug candidates will result in any approved products
in the U.S. or any other country. Please view these and other
risks described in the Company's filings with the Securities and
Exchange Commission ("SEC"), including those identified in the
"Risk Factors" section of the annual report on Form 10-K for the
year ended December 31, 2014, and
subsequent quarterly reports filed on Form 10-Q, as well as other
filings it makes with the SEC. Any forward-looking statements in
this press release represent the Company's views only as of the
date of this release and should not be relied upon as representing
its views as of any subsequent date. The Company specifically
disclaims any obligation to update this information, as a result of
future events or otherwise, except as required by applicable
law.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/regenerx-to-present-at-2-investor-conferences-300086663.html
SOURCE RegeneRx Biopharmaceuticals, Inc.